GLP-1 has transformed the treatment of obesity, demonstrating “unprecedented effectiveness” in weight reduction. Yet many patients stop these medications due to side effects or cost, and weight regain is common.
A recent meta-analysis found that about half of GLP-1 users stopped treatment within the first year. Most regained about 60% of the weight lost within a year of stopping treatment. Another meta-analysis, involving more than 9,300 patients, published in The BMJfound that people returned to their pre-treatment weight 1.7 years on average after stopping treatment.
“Obesity is like any other chronic illness,” said Marsha Novick, MD, medical director of Weight Management & Wellness Online. Medscape Medical News. “For example, we might anticipate that stopping asthma medications would cause asthma symptoms to worsen. The same thing happens when stopping obesity medications.”
Novick, a spokesperson for the Obesity Society, noted that weight regain is broadly similar between GLP-1 drugs.
“No particular GLP-1 was found to provide more protection than other GLP-1s against rebound weight gain once treatment was stopped,” she said.
Powerful biological mechanisms
Weight regain after GLP-1 discontinuation reflects several intersecting processes, including the return of appetite.
Sam West, PhD, postdoctoral researcher at the Nuffield Department of Primary Care Health Sciences, University of Oxford, UK, and lead author of The BMJ meta-analysis, explained that the appetite-suppressing effects of GLP-1 drugs diminish after stopping.
“Once you stop taking the drug, that feeling of hunger comes back quickly. It’s not as simple as controlling what you eat. You’re fighting powerful biological mechanisms,” he said. Medscape Medical News.
Franchell Hamilton, MD, bariatric surgeon and founder of the NeuroSwitch Weight Loss Institute, also noted the return of hunger and cravings.
“GLP-1 drugs chemically suppress appetite and reduce “food noise.” When interrupted without addressing the underlying neurological habit loops or metabolic adaptations, hunger signals rebound abruptly, often accompanied by increased cravings, which lead to weight gain,” she said.
Behavioral and psychological factors, including stress eating, increased portion sizes, loss of confidence, and weight stigma, also contribute to weight regain. The modern obesogenic environment, characterized by ultra-processed foods, sedentary behavior, and socioeconomic barriers, may compound these challenges.
The plateau effect
Although weight regain is common, not everyone who stops GLP-1 regains their pre-treatment weight.
A meta-analysis published in eMedicineClinical found that weight regain was faster during the first months after stopping treatment. After one year, it is estimated that weight regain stabilizes at around 75% of the initial weight loss.
Researchers have proposed several explanations for this plateau effect, including the possibility that healthier eating habits adopted during treatment persist after treatment stops. GLP-1 may also exert beneficial long-term physiological effects.
Novick pointed out that there is a wide variation in the amount of weight regained.
“We can expect most people to regain about half to two-thirds of the weight they lost within a year of stopping treatment. This means that a person can still end up weighing less than before they started GLP-1 treatment,” she said.
Strategies before quitting
“The best advice I can give is for people to continue taking their (GLP-1) medications,” West said.
For patients who cannot do this, switching to another GLP-1 drug may be an option. A 2020 consensus statement noted that patients may respond differently to individual agents, making switching potentially viable when intolerable side effects, costs, formulary changes, or insurance mandates interfere with treatment.
West also suggested that switching from an injectable to an oral formulation of the same drug could be helpful.
He noted, however, that there was a lack of robust, evidence-based guidance on discontinuation strategies, given the relative newness of GLP-1s.
Nonetheless, a 2026 editorial published in American family physician described three potential approaches:
- Dose reduction: Gradually reduce the dose at controlled intervals to limit weight regain and sudden increases in appetite. Preliminary research suggests that tapering semaglutide alongside lifestyle interventions may help maintain weight loss for at least 20 weeks after stopping treatment.
- Dosing at intervals: Gradually lengthen the time between injections, taking advantage of the long half-life of these medications. A small chart review revealed that patients who achieved their weight and/or metabolic goals maintained their weight loss with dosing every two weeks over an average of 32 weeks.
- Adding an oral medication for obesity: Introduction of a medication such as phentermine or phentermine-topiramate during dose reduction to supplement appetite suppression.
The authors emphasized that these cessation strategies must be “coupled with a renewed commitment to lifestyle modifications.”
Structured Lifestyle Support
Novick agreed with the need to incorporate such modifications into pre-cessation strategies, pointing to research suggesting that adding regular aerobic exercise to obesity drug therapy may help minimize weight regain after cessation.
A recently published randomized study also examined the potential benefits of structured support. Adults who had lost weight while taking GLP-1 medications were assigned after stopping to usual care, a digital wellness app, or medically tailored meals delivered to their homes.
Compared to usual care, both intervention groups experienced significantly less weight gain over 4 months. The differences were -7.16% with the digital intervention and -7.17% with the medically adapted meals.
“We found that participants who received medically tailored meals or behavioral support were better able to maintain their weight loss than participants receiving usual care, up to 4 months after stopping treatment,” said lead author Kelseanna Hollis-Hansen, PhD, MPH, research assistant professor at the Food is Medicine Institute at Tufts University, in Boston, Massachusetts. Medscape Medical News.
“Although larger, longer studies are needed, our results suggest that structured lifestyle support can help people navigate this difficult transition and maintain some of the health benefits they gained from taking the medication,” she said.
Hollis-Hansen, who is also a consultant and program advisor at the Center for Nutrition and Health Impact, emphasized the importance of continued monitoring.
“Continued monitoring can help determine whether patients may benefit from further dose titration, switching to another anti-obesity medication, or intensifying behavioral treatment,” she said.
A multidisciplinary approach involving nutrition, mental health, exercise and individualized medical management can provide additional support.
Beyond standard diet advice
According to Hamilton, author of Transformation is a state of mind: the journey to change your contribution and your world, it is essential to “go beyond standard dietary advice, which is often insufficient when it focuses solely on counting calories or tracking macronutrients rather than the underlying factors of eating behaviors.”
She considers “active behavioral wiring to be the essential missing link in post-GLP-1 maintenance.”
During GLP-1 treatment, appetite is passively suppressed, which may reduce opportunities to train yourself to manage cravings, Hamilton explained. Once treatment is stopped, patients may have difficulty coping with the return of hunger and the sound of food.
She recommends behavioral techniques that disrupt automatic habits and help patients recognize and interrupt their responses to stress, fatigue, and environmental eating cues while they are still on the medication.
Hamilton uses this approach through her proprietary NeuroSwitch method, which she offers to patients undergoing bariatric surgery or taking weight-loss medications.
Cognitive behavioral therapy (CBT) has an established role in long-term weight management. Mindfulness and acceptance-based approaches can complement CBT by helping patients respond differently to cravings and food-related triggers.
The role of bariatric surgery
For some patients who regain weight after stopping GLP-1 treatment, metabolic and bariatric surgery may be an option.
Novick suggested that surgery might be appropriate for some patients with a BMI greater than 35 kg/m2.
“It often helps people lose about one in every 3 to 4 pounds of their body weight and many keep much of it off for 10 years or more,” she said.
Hamilton also highlighted the potential role of surgery for patients with severe obesity or metabolic diseases who have difficulty maintaining drug therapy or who experience a plateau in weight loss, noting that “bariatric surgery remains one of the most enduring interventions by permanently altering metabolic signaling, gut peptides, and hunger physiology.”
Talking to patients about GLP-1
West emphasized the importance of discussing management plans early in GLP-1 treatment.
“Have in-depth conversations about long-term planning Before “Patients are starting to take these medications,” he said. “Patients should be aware that they could be taking them for life and that the risk of weight regain (on stopping) should be clearly indicated from the start.”
Hollis-Hansen encouraged clinicians to explain that “increased difficulty maintaining weight after stopping a GLP-1 medication is not a sign of failure.”
Patients must understand that weight regulation is “complex, biologically motivated, and strongly…
Gn Health
